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The aim of this study was to investigate the role of circulating growth hormone (GH), insulin growth factor-1 (IGF-1), IGF
binding protein-3 (IGFBP-3), and nitric oxide (NO) concentrations in the patients suﬀering from Parkinson’s disease (PD). The
study groups were consisted of 25 patients with PD and 25 matched healthy subjects as a control. The NO level of patients in PD
group (2.3 ± 0.4µmol/L) was signiﬁcantly lower than that in the control group (2.8 ± 0.6µmol/L) (P:.011). Although there were
no statistically signiﬁcant diﬀerences in the GH, IGF-1, and IGF BP-3 levels among the two groups, in this preliminary study, we
foundlowNOandmildlyelevatedIGF-1levelsinthepatientswithPD.Theresultsmaybeassociatedwithadaptationorprotective
mechanisms in the neurodegenerative disease processes such as seen in the PD. Further studies should be carried out to conﬁrm
our results.
Copyright © 2009 Deniz Tuncel et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Parkinson’s disease (PD) is a common neurodegenerative
disorder that can cause signiﬁcant disability and decline in
the quality of life. It is not a single entity simply resulting
from a dopaminergic deﬁcit, rather most likely caused by
a combination of genetic predisposition and environmental
factors. Mitochondrial dysfunction has been proposed as a
general basic mechanism underlying the neurodegeneration
seen in PD [1, 2]. This condition is related to increased
free radical production, oxidative stress, and decreased ATP
production, that leads to increased intracellular calcium
concentration, excitotoxicity, and nitric oxide related cellular
damage [1, 3, 4].
Nitric oxide (NO) has varied physiological roles in
the nervous system, including morphogenesis and devel-
opmental synaptic plasticity. However, in the pathological
conditions, it could contribute to the oxidative stress and
neurodegeneration [4, 5]. Clinical ﬁndings, evidences from
experimental models, and postmortem studies revealed
a connection of NO with the selective degeneration of
dopaminergic neurons in the PD [4, 6]. Formation of NO
can be regulated via the GH-IGF-1 system, but the cellular
mechanism for this regulation is unknown [7]. Growth
hormone (GH) exerts much of its biological activity by
stimulating the production of (IGF-1), which is synthesized
in nearly every tissue including the central nervous system.
Insulin and IGF-1 have metabolic, neurotrophic, neuro-
modulatory, and neuroendocrine important functions in the
brain. Studies among older people suggest that the GH-
I G F - 1a x i sa c t i v i t yi sr e d u c e dw i t ha g e[ 7–9]. Thus, IGF-
1 deﬁciency may be involved in the pathogenesis of age-
related neurodegenerative diseases and might be relevant to
the etiology of PD [8–10].
To further reveal the pathophysiological processes that
were seen in the PD, we aimed to investigate the role of
circulating GH, IGF-1, IGFBP-3, and NO concentrations in
the PD patients in comparison with healthy subjects.
2.MaterialsandMethods
After receiving approval from the Hospital’s Ethics Com-
mittee, we recruited patients from the out-patient clinic
of our Neurology Department. All subjects had signed
writteninformedconsentbeforeparticipation. Aneurologist
performed physical examination of each patient and noted2 Mediators of Inﬂammation
the patient history. All PD patients showed rest tremor,
rigidity, bradykinesia, and postural instability. These features
with any one had begun displayed asymmetry. Patients with
Parkinsonism, stroke, and dementia were excluded from the
study. The patients with PD and healthy control groups were
consisted of nonsmokers without other neurodegenerative,
chronic, or infectious diseases. There were 25 patients in the
PD group and 25 matched healthy subjects in the control
group.TherevisionofHoehnandYahrstagingscalewasused
to estimate the disease severity [11]. All of the PD patients
were under the treatment with anti-PD drugs.
Venous blood samples were collected at 8AM and 9AM
after an overnight fasting period. Within 1 hour after
blood taking, the blood was centrifuged at 4000rpm for 10
minutes, and the serum was stored at −70
◦C until analyzed.
Stored sera were assayed for IGF-1, IGFBP-3, and GH by
an automated chemiluminescent assay system (IMMULITE
2000, Diagnostic Products Corp., Los Angeles, Calif, USA).
Serum nitric oxide measurement was performed using the
Griess method for detection of nitrite levels [12].
Statistical assessments were carried out with SPSS 10.0
packet program. All data were given as mean ± standard
deviation (SD). The results were analyzed using the Mann-
Whitney U-test. A P-value of less than .05 was considered
statistically signiﬁcant.
3. Results
There were 25 patients (20 males, 5 females) in the PD group
with a mean age of 67.9 ± 9.4 years, and 25 healthy subjects
(20 males, 5 females) in the control group with a mean age
of 64.3 ± 8 years. Age and sex distributions of patients and
control groups were similar (P>. 05). The mean Hoehn
and Yahr stage was 3, and the duration of PD was 4.9 ± 3.1
years (see Table 1). NO, IGF-1, and IGFBP-3 levels in serum
of PD patients showed no correlation with the duration and
severity of the disease (measured by the Hoehn and Yahr
staging scale).
The NO level of patients in PD group (2.3 ± 0.4µmol/L)
was signiﬁcantly lower than that in the control group (2.8 ±
0.6µmol/L) (P:.011). However, there were no statistically
signiﬁcant diﬀerences in the GH, IGF-1, IGFBP-3 levels
among the patient and the control group (P>. 05) (see
Table 2).
4. Discussion
Mitochondria are critical regulators of cell death and have
been implicated as an important player in the death of
dopaminergic neurons in PD. NO has been suggested to
contribute, via impairment of mitochondrial function, to
the neurodegenerative process [1, 3, 4]. It has previously
been shown that formation of NO can be regulated via the
GH-IGF-1 system, and this system may prevent the NO-
mediated neuronal damage. But, the cellular mechanism for
this regulation is unknown [9]. We found that the NO level
of patients in the PD group was signiﬁcantly lower than that
incontrols.Althoughstatisticallynotsigniﬁcant,IGF-1levels
were mildly elevated in the patients with PD. These changes
Table 1: Age, sex, and clinic features of the patients with PD and
healthy controls.
Patients Controls
Age (years)
mean ±SD 67.9 ±9.46 4 .3 ±8
Sex
Male (n)2 0 2 0
Female (n)5 5
Hoehn and Yahr score
mean ±SD 3 ±1
Duration of illness
men ±SD 4.9 ±3.1
Table 2: Nitric oxide, growth hormone, insulin-like growth factor-
1, and insulin-like growth factor BP-3 levels of the patients with PD
and healthy controls.
Patients Controls
Nitric oxide (µmol/L)
mean ±SD 2.3 ±0,4 2.8 ±0.6
∗
Growth hormone (ng/mL)
mean ±SD 0.9 ±0.90 .7 ±1.2
Insulin-like growth factor-1 (ng/mL)
(mean ±SD) 132 ±42 113 ±51
Insulin-like growth factor BP-3 (µg/mL)
(mean ±SD) 3.4 ±0.83 .7 ±1
∗P:.011, P:.52, P:.087, P:.19, respectively.
may be considered to reﬂect local adaptive and protective
responses to an underlying pathological derangement [3, 5,
9, 13].
The excess of NO could contribute to the formation
of free radicals that could be involved in the death of
dopaminergic neurons, leading to the development of PD
symptoms [4]. Studies on nitrite and nitrate measurements
in the cerebrospinal ﬂuid (CSF) of PD patients have been
contradictory, as there was no change [14–16], increase
[17, 18], or decrease [19, 20]. On the other hand, some
studies showed that CSF and plasma nitrate levels did not
correlate with age at onset, duration, scores of the uniﬁed
Parkinson’sdiseaseratingscales,andHoehnandYahrstaging
in the patients group [15, 16]. NO-mediated neurotoxic
and neuroprotective eﬀects seem to be dependent on its
oxidative/reductive status, and the exact contribution to
neurodegeneration is still not completely understood. An
involvement of NO in the protective eﬀect may occur via
adaptive mechanisms. Therefore, the excessive NO syn-
thesized in the course of adaptation is stored against the
detrimental eﬀects [4–6, 13]. We found that the nitric oxide
level of patients in the PD group was signiﬁcantly reduced
than that in controls. The possible explanations for these
low levels may be a defective NO-dependent adaptation
mechanism or the exhaustion of NO storage in the course
of PD. However, we found no signiﬁcant correlation between
these levels and the duration of disease and Hoehn and Yahr
staging.Mediators of Inﬂammation 3
G r o wt hh o rm o n ee x e rt sm u c ho fi t sb i o l o gi c a la c t i vi tyb y
stimulating the production of IGF-1, which is synthesized in
nearly every tissue including the central nervous system and
bounds to IGFBP-3. The GH-IGF-1 axis activity is reduced
with age. Various studies showed that declining levels of
serum IGF-1 contribute to age-associated brain impairments
and neurodegenerative diseases such as PD and Alzheimer’s
[9, 21]. Also, IGF-I has recently been found of potential ther-
apeutically use in diﬀerent neurodegenerative conditions.
Substantia nigra is one of the regions in the human brain,
where a considerable density of IGF-1 receptors is evident.
IGF-1 increases the survival of neurons in the brain stem and
rescues embryonic DA neurons from programmed cell death
[9, 22, 23]. It is found that serum IGF-1 levels are variable
in the diﬀerent diseases [9]. There were no statistically
signiﬁcant diﬀerences in the IGF-1 and IGFBP-3 levels
among our patient and control groups. After a pathological
condition develops, IGF-1 levels increase to protect aﬀected
neurons and to adapt to an underlying pathological process.
ThismechanismmayexplainthemildlyelevatedIGF-1levels
[9].
Our study has some limitations; our patient group is
rather small and had a male predominance. The results of
this preliminary study must be conﬁrmed in larger patient
groups with diﬀerent age and sex distributions.
As a conclusion, there are few data about the role of NO
on IGF-1, IGFBP-3 gene expression, and serum levels in PD.
In this preliminary study, we found that there were low NO
and mildly elevated IGF-1 levels in the patients. The results
may be associated with adaptation or protective mechanisms
intheneurodegenerativediseasesprocesssuchasPD.Further
studies should be carried out to conﬁrm these results.
References
[ 1 ]P .M .A b o u - S l e i m a n ,M .M .K .M u q i t ,a n dN .W .W o o d ,
“Expanding insights of mitochondrial dysfunction in Parkin-
son’s disease,” Nature Reviews Neuroscience,v o l .7 ,n o .3 ,p p .
207–219, 2006.
[2] C. Nunes, L. Almeida, and J. Laranjinha, “Synergistic inhi-
bition of respiration in brain mitochondria by nitric oxide
and dihydroxyphenylacetic acid (DOPAC): implications for
Parkinson’s disease,” Neurochemistry International, vol. 47, no.
3, pp. 173–182, 2005.
[ 3 ]S .J .R .H e a l e s ,A .A .J .L a m ,A .J .D u n c a n ,a n dJ .M .L a n d ,
“Neurodegeneration or neuroprotection: the pivotal role of
astrocytes,” Neurochemical Research, vol. 29, no. 3, pp. 513–
519, 2004.
[4] R. Kavya, R. Saluja, S. Singh, and M. Dikshit, “Nitric oxide
synthase regulation and diversity: implications in Parkinson’s
disease,” Nitric Oxide, vol. 15, no. 4, pp. 280–294, 2006.
[5] B. Br¨ une, “Nitric oxide: NO apoptosis or turning it ON?” Cell
Death & Diﬀerentiation, vol. 10, no. 8, pp. 864–869, 2003.
[6] S. Singh and M. Dikshit, “Apoptotic neuronal death in Parkin-
son’s disease: involvement of nitric oxide,” Brain Research
Reviews, vol. 54, no. 2, pp. 233–250, 2007.
[7] T.Pirttil¨ a,S.Vanhatalo,U.Turpeinen,andR.Riikonen,“Cere-
brospinal ﬂuid insulin-like growth factor-1, insulin growth
factor binding protein-2 or nitric oxide are not increased in
MS or ALS,” Acta Neurologica Scandinavica, vol. 109, no. 5, pp.
337–341, 2004.
[8] S.Busiguina,A.M.Fernandez,V.Barrios,etal.,“Neurodegen-
eration is associated to changes in serum insulin-like growth
factors,” Neurobiology of Disease, vol. 7, no. 6, pp. 657–665,
2000.
[9] J. L. Trejo, E. Carro, E. Garcia-Galloway, and I. Torres-
Aleman, “Role of insulin-like growth factor I signaling in
neurodegenerative diseases,” Journal of Molecular Medicine,
vol. 82, no. 3, pp. 156–162, 2004.
[10] D. Oﬀen, B. Shtaif, D. Hadad, A. Weizman, E. Melamed,
a n dI .G i l - A d ,“ P r o t e c t i v ee ﬀect of insulin-like-growth-factor-
1 against dopamine-induced neurotoxicity in human and
rodent neuronal cultures: possible implications for Parkin-
son’s disease,” Neuroscience Letters, vol. 316, no. 3, pp. 129–
132, 2001.
[11] C. G. Goetz, W. Poewe, O. Rascol, et al., “Movement Disorder
SocietyTaskForcereportontheHoehnandYahrstagingscale:
statusandrecommendations.TheMovement DisorderSociety
Task Force on rating scales for Parkinson’s disease,” Movement
Disorders, vol. 19, no. 9, pp. 1020–1028, 2004.
[12] N. K. Cortas and N. W. Wakid, “Determination of inorganic
nitrate in serum and urine by a kinetic cadmium-reduction
method,” Clinical Chemistry, vol. 36, no. 8, pp. 1440–1443,
1990.
[13] E. B. Manukhina, S. Yu. Mashina, B. V. Smirin, et al., “Role
of nitric oxide in adaptation to hypoxia and adaptive defense,”
Physiological Research, vol. 49, no. 1, pp. 89–97, 2000.
[14] J. R. Sanchez-Ramos, E. Overvik, and B. N. Ames, “A
marker of oxyradical-mediated DNA damage. (8-hydroxy-
2 deoxyguanosine) is increased in nigro striatum of Parkin-
son’s disease brain,” Neurodegen, vol. 3, pp. 197–204, 1994.
[15] J. A. Molina, F. J. Jim´ enez-Jim´ enez, J. A. Navarro, et al.,
“Cerebrospinal ﬂuid nitrate levels in patients with Parkinson’s
disease,” Acta Neurologica Scandinavica,v o l .9 3 ,n o .2 - 3 ,p p .
123–126, 1996.
[16] R. Shukla, M. Rajani, N. Srivastava, M. K. Barthwal, and
M. Dikshit, “Nitrite and malondialdehyde content in cere-
brospinal ﬂuid of patients with Parkinson’s disease,” Interna-
tional Journal of Neuroscience, vol. 116, no. 12, pp. 1391–1402,
2006.
[17] J. Kalra, A. H. Rajput, S. V. Mantha, A. K. Chaudhary,
and K. Prasad, “Oxygen free radical producing activity of
polymorphonuclear leukocytes in patients with Parkinson’s
disease,” Molecular and Cellular Biochemistry, vol. 112, no. 2,
pp. 181–186, 1992.
[18] G. A. Qureshi, S. Baig, I. Bednar, P. Sodersten, G. Forsberg,
and A. Siden, “Increased cerebrospinal ﬂuid concentration of
nitrite ire Parkinson’s disease,” NeuroReport, vol. 6, no. 12, pp.
1642–1644, 1995.
[19] M. A. Kuiper, J. J. Visser, P. L. M. Bergmans, P. Scheltens, and
E. C. Wolters, “Decreased cerebrospinal ﬂuid nitrate levels in
Parkinson’s disease, Alzheimer’s disease and multiple system
atrophy patients,” Journal of the Neurological Sciences, vol. 121,
no. 1, pp. 46–49, 1994.
[20] J. Huski´ c, A. Paperniku, A. Husi´ c, F. Alendar, and N. Mula-
begovi´ c, “Signiﬁcantly reduced salivary nitric oxide synthesis
in patients with Parkinson’s disease,” Bosnian Journal of Basic
Medical Sciences, vol. 5, no. 3, pp. 86–89, 2005.
[21] E. Carro and I. Torres-Aleman, “The role of insulin and
insulin-like growth factor I in the molecular and cellular
mechanismsunderlyingthepathologyofAlzheimer’sdisease,”
E u r o p e a nJ o u r n a lo fP h a r m a c o l o g y , vol. 490, no. 1–3, pp. 127–
133, 2004.4 Mediators of Inﬂammation
[22] J. Guan, R. Krishnamurthi, H. J. Waldvogel, R. L. M. Faull,
R. Clark, and P. Gluckman, “N-terminal tripeptide of IGF-1
(GPE) prevents the loss of TH positive neurons after 6-OHDA
induced nigral lesion in rats,” Brain Research, vol. 859, no. 2,
pp. 286–292, 2000.
[23] R. Krishnamurthi, S. Stott, M. Maingay, et al., “N-terminal
tripeptide of IGF-I improves functional deﬁcits after 6-OHDA
lesion in rats,” NeuroReport, vol. 15, no. 10, pp. 1601–1604,
2004.